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RatOrexin-A and orexin-B are two neuropeptides selectively synthesized in the lateral hypothalamus (LH), a region
involved in morphine induced analgesia and pain modulation. Furthermore, orexin-A has been reported to pro-
duce an analgesic effect in pain models, which was blocked by orexin-1 receptor antagonist SB-334867, but not
naloxone. We studied the effects of intracerebroventricular (ICV) injection of SB-334867, a selective orexin re-
ceptor type-1 antagonist, onmorphine-induced antinociceptive effect in formalin test in rats.Morphine injection
at a dose of 1.5mg/kg caused a significant decrease in the formalin-induced nociceptive behaviors in phase 1, in-
terphase, and phase 2A, whereas at doses of 3, 6, and 10mg/kg, a significant reduction in the formalin-induced
nociceptive behaviors was observed in all phases. The ICV injection of SB-334867 alone had no effect on the
formalin-induced nociceptive behaviors. Pre-treatment with SB-334867 at a dose of 0.5nmol significantly atten-
uated the analgesia induced by morphine (at dose 1.5mg/kg of morphine; interphase and phase 2B and at dose
3mg/kg ofmorphine just phase 2B of formalin test). Also, pre-treatmentwith SB-334867 at a dose of 5nmol con-
siderably attenuated the morphine-induced analgesia (at dose 1.5mg/kg of morphine; phase 1, interphase, and
phase 2, at dose 3 and 6mg/kg ofmorphine just phase 2 of formalin test). Pre-treatmentwith SB-334867 at a dose
of 50 nmol remarkably attenuated the morphine-induced analgesia (at dose 1.5 and 3 mg/kg of morphine; in
phase 1, interphase, and phase 2 and also at dose 6 mg/kg of morphine; phase 1 and phase 2B of formalin
test). These data suggest that the antinociceptive effects of morphine in formalin test might be associated with
orexin receptor type-1. Our findings reveal a new role for the lateral hypothalamus orexin neurons in the
morphine-induced analgesia.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
Morphine, themost abundant alkaloid found in opium, is a potent
analgesic and frequently used drug for the treatment of both acute
and chronic pain. There are spinal and supra-spinal mechanisms
governing the analgesic effect of systemically injected morphine
(Barton et al., 1980). Morphine activates the top-down descending
modulating inhibitory systems in the supraspinal regions such as the ros-
tral ventromedialmedulla (RVM),whichfinally inhibited thefirst synap-
se in the dorsal horn neurons (Basbaum and Fields, 1984). Also, through
another mechanism, morphine directly affects the first synapse of dorsal
horn neurons, inhibiting the transmission of nociceptive information to
supra-spinal centers (Yaksh and Noueihed, 1985).
The lateral hypothalamus (LH) that exclusively expresses orexin has
a very important role in the modulation of nociceptive behavior (Dafnyesearch Center, Department of
el./fax: +98 281 3324971.
ri-Zarmehri),
ghts reserved.et al., 1996; Franco and Prado, 1996; Holden and Pizzi, 2008). The stim-
ulation of LH produces an antinociceptive effect in both acute and tonic
pain (Dafny et al., 1996; Franco and Prado, 1996; Holden and Naleway,
2001). Additionally, the stimulation of LH elicits antinociception via re-
lays to the brain stem sites such as; periaqueductal gray matter (PAG)
and the RVM, which ultimately effect on descending inhibitory
pathways (Behbehani et al., 1988). Morphine microinjection into the
LH significantly decreases nociceptive behaviors on the tail flick and
formalin-induced nociceptive behaviors (Fuchs and Melzack, 1995;
Dafny et al., 1996; Franco and Prado, 1996), suggesting that the LH can
be considered as one of the centers in the supraspinal region that modu-
lates nociceptive behaviors (Lopez et al., 1991; Lopez and Cox, 1992;
Fuchs and Melzack, 1995; Dafny et al., 1996; Franco and Prado, 1996).
In a study by Jain et al., it was shown that the LH lesions produced a
hyperalgesic effect as demonstrated by a decrease in the tail flick latency
(Jain et al., 2001).
Recently, two new neuropeptides; the orexin-A and orexin-B (also
called hypocretin-1 and hypocretin-2) have been described in the neu-
rons of the LH and perifornical area. These neuropeptides are reported
to have broad projections, leading to the recognition of their roles in
65H. Azhdari-Zarmehri et al. / Pharmacology, Biochemistry and Behavior 112 (2013) 64–70the regulation of a variety of functions including feeding, sleep–wake
cycle, cardiovascular function, hormone secretion (Ferguson and
Samson, 2003; Siegel, 2003; Sakurai, 2005; Samson et al., 2005),
and more recently the modulation of nociceptive processing (Bingham
et al., 2001; Yamamoto et al., 2003a; Suyama et al., 2004; Mobarakeh
et al., 2005b; Azhdari-Zarmehri et al., 2011; Sadeghi et al., 2013). The
antinociceptive effect of orexin-A which is blocked by orexin-1 receptor
antagonist SB-334867 but not naloxone, ruled out the involvement of
endogenous opiate system in these effects (Bingham et al., 2001;
Yamamoto et al., 2002; Cheng et al., 2003). Furthermore, the stress-
induced antinociceptive effect was prevented by SB-334867 (Heidari-
Oranjaghi et al., 2012) and the antagonismof orexin receptor 1 decreased
the development ofmorphine tolerance and physical dependence (Erami
et al., 2012b). In another study, we showed that the orexinergic projec-
tions from the LH to the ventral tegmental area and the nucleus accum-
bens are direct/indirectly involved in the antinociception induced by LH
chemical stimulation, and orexin-1 and -2 receptors in the ventral teg-
mental area have a more substantial role in this phenomenon (Sadeghi
et al., 2013; Azhdari-Zarmehri et al., 2013). Orexin-A and their receptors
are localized in the areas of the brain and spinal cord associated with no-
ciceptive processing such as the periaqueductal gray (PAG) and locus
coeruleus (LC) (Peyron et al., 1998). These studies that emphasize the an-
algesic effect of orexin-A (Bingham et al., 2001; Chiou et al., 2010;
Azhdari-Zarmehri et al., 2011; Ho et al., 2011; Erami et al., 2012a) and
the pattern of localization of both peptide and receptor in the areas in-
volved in painmodulation provide a strong evidence for orexin-A in hav-
ing a role in the modulation of morphine-induced analgesia. Recently,
using in-situ hybridization, Georgescu et al. (2003) have demonstrated
that all orexin-A cells that respond to chronic morphine administration
and opiate antagonist-precipitated morphine withdrawal also express
the μ-opioid receptor, suggesting a direct mode of action (Georgescu
et al., 2003).
The stimulation of LH or the microinjection of morphine into the
LH produces an analgesic effect (Holden et al., 2002; Holden et al.,
2005). Moreover, orexin-A is exclusively produced in the LH and
since it has an essential role in pain modulation, and that the orexin
induced antinociceptive effect mediated through orexin receptor 1,
we hypothesized that the blockade of orexin receptor type-1 by SB-
334867 prevents the morphine-induced antinociceptive effect in
the formalin test. We used the formalin test as a tonic pain test to
quantify the effect of the antagonism of orexin receptor type-1 on
the morphine induced analgesia. The formalin-induced nociceptive
behavior was used because it is a model of inflammation that lasts
long enough, during which the experimental animals show a sponta-
neous response. Moreover, the pain stimulus is a continuous rather
than a transient one and may thus have resemblance to some kinds
of clinical pain and that the observations are made on animals that
are restrained lightly or not at all.2. Materials and methods
2.1. Subjects
All experiments involving the animals were conducted according
to the policy of Iranian Convention for the Protection of Vertebrate
Animals Used for the Experimental Purposes, and the protocol was
approved by the Ethics Committee of the School of Medicine, Qazvin
University of Medical Sciences, Qazvin, Iran. Adult Wistar rats
(220–300 g) were purchased from Razi Institute (Karaj, Iran). Ani-
mals were housed in groups of 8 rats per big cage (cage size was
58 × 40 × 22 cm), at a temperature-controlled room, under a 12 h
light–dark cycle with lights on at 7:00 to 19:00. Food and water
were provided ad libitum. In all experiments, attention was paid to
the regulations of the local authorities for handling of laboratory
animals.2.2. Drugs
Two percent formalin was diluted (Temad, Iran) with sterile physio-
logical saline solution (Soha, Iran). Morphine sulfate (Temad, Iran) was
dissolved in saline. OX1R antagonist; SB-334867 (N-(2-methyl-6-
benzoxazolyl)-N′-1,5-naphthyridin-4-yl urea); (molecular weight =
356, Tocris), was dissolved in dimethyl sulfoxide (DMSO, stock solu-
tion) and diluted in saline on the day of experiment (DMSOwas initially
prepared as 10/100 in 0.9%w/v saline solution and further diluted 1/100
and 1/1000). All drugswere diluted in saline immediately before use on
the morning of experiment.
2.3. Surgical preparation for ICV microinjections
To perform direct ICV administrations of drugs or respective vehicle,
the guide cannula was implanted 7 days before the experiments. Rats
were anesthetized with ketamine (100 mg/kg)/xylazine (10 mg/kg)
and a 23-gauge stainless steel guide cannula, 2mm long was stereotax-
ically (Stoelting) lowered until its tip was 2 mm above the right
cerebroventricular by applying coordinates from the atlas of Paxinos
and Watson (2005) [0.9 mm caudal to bregma, 1.8 mm lateral to the
midline and 3.8mm depth]. Using dental cement, the cannula was an-
chored on two stainless steel screws in the skull. Immediately afterwak-
ing from surgery, rats were returned to their home cages to await the
formalin test procedure. On the day of experiment, rats were trans-
ferred to individual cages and allowed to acclimatize for 60min before
they were put in an acrylic observation chamber. Direct ICV administra-
tion of drugs or respective vehicle, was conducted with a stainless steel
cannula (30G, 0.3 mm outer diameter) connected by a polyethylene
tube to a 26-gauge Hamilton syringe, inserted through the guide cannu-
la and extended 2mm beyond the tip of the guide cannula to reach the
right cerebroventricular area. SB-334867 (0.5, 5 and 50nmol; ICV) was
microinjected 5min (Heidari-Oranjaghi et al., 2012; Erami et al., 2012b)
before morphine injection (1.5, 3, 6, and 10mg/kg, S.C.) followed by the
performance of formalin test 30 min later. Drug solutions or vehicles
(5 μl) were injected ICV over a period of 60 s and the injection cannula
was gently removed 1 min later. After 30 min, formalin was injected
into the plantar surface of the right hind paw using a disposable insulin
syringe with a fixed 30G needle.
2.4. Formalin test
Rats weremoved to the test room at least 1h before the commence-
ment of experiment. Formalin tests were performed in clear plastic
boxes (30× 30×30 cm) with a mirror placed underneath at 45° angle
to allow anunimpeded viewof the animals' paws. Initially, ratswere ac-
climatized for 30 min in an acrylic observation chamber followed by
injecting 50 μl of 2% formalin subcutaneously into the plantar surface
of the right hind paw using a 30 gauge needle. To ensure stable scores
from the formalin-induced nociceptive behaviors, it was necessary to
make sure that the needle was inserted through the skin and run for
5mm under the skin. Each rat was immediately returned to the obser-
vation box and the behavioral recording began. Behavioral scoring
was performed by a subtle modification of the method originally de-
scribed by Dubuisson and Dennis (1977) in which they employed four
behavioral categories. Nociceptive behaviors were scored as follows: 0,
the injected paw was not favored; 1, the injected paw had little or no
weight placed on it; 2, the injected pawwas elevated and not in contact
with any surface; and 3, the injected pawwas licked or bit. Recording of
nociceptive behaviors started immediately after formalin injection
(time 0) and continued for 90min. The scores of nociceptive behaviors
for each 3-minute interval were calculated as the weighted average
of the number of seconds, spent in each nociceptive behavior, from
the beginning of experiment. The scores were recorded in vehicle rats
aswell as those receiving the drug. In each group, the average behavior-
al responses of each rat during the first (1–7min), inter-phase (8–14),
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the data were reported as the time average of nociceptive behaviors.
2.5. Experimental protocols
The formalin test was the experimental procedure used in our
study to examine the effect of antagonizing OX1R on the morphine
antinociceptive effect. Three sets of experiments were considered in
the formalin test: (Experiment 1) Rats were given only morphine injec-
tion (1.5, 3, 6 and 10mg/kg) followed by the performance of formalin
test. (Experiment 2) Rats had ICV microinjection of SB-334867 (0.5, 5
and 50nmol) or 1% DMSO followed by morphine injection (1.5mg/kg)
and formalin test was pursued 30min later. (Experiment 3) Rats were
given SB-334867 (0.5, 5 and 50 nmol) by ICV microinjection or 1%
DMSO followed by morphine injection (3mg/kg) and 30min later, the
formalin test was performed. (Experiment 4) Rats received SB-334867
(0.5, 5 and 50 nmol) by ICV microinjection or 1% DMSO followed by
morphine injection (6mg/kg) and after 30min, the formalin test was
carried out. In all experiments, morphinewasmicroinjected subcutane-
ously; SB-334867 microinjected into the right cerebroventricular area,
and formalin injected into the plantar surface of the right hind paw.
2.6. Data analysis
Datawere presented asmean±SEMand analyzed by one-way anal-
ysis of variance between the groups. The total time points of 90minutes
duration were divided into four phases as phase 1 (minutes 0 to 7),
interphase (minutes 8 to 14), phase 2A (minutes 15 to 60), and phase
2B (minutes 61 to 90). The Tukey's test was employed to determine
where a significant difference occurred. The defined level for statistical
significance was Pb0.05.
3. Results
3.1. Effects of different doses of morphine through subcutaneous injection
on formalin-induced nociceptive behaviors
Fig. 1 indicates the results of experiment 1. Formalin produced typi-
cal biphasic pain responses. The first and second phases were separated
by a brief inter-phase where little or no nociceptive behavior was ob-
served in the control group (Fig. 1). Morphine injection at 1.5 mg/kg
30 min before the formalin test significantly decreased formalin-
induced nociceptive behaviors in phase 1 (p b 0.05), interphase
(p b 0.001), and phase 2A (p b 0.05) compared with the control groupFig. 1. Formalin-induced nociceptive behaviors (mean±SEMof 6 rats per group) following sub
(A) and the bar chart (B). The columns represent the average nociceptive scores in eachphase: p
(minutes 61–90). Rats received morphine 30 min before formalin injection. Recording of noci
90min. *P b 0.05; **P b 0.01; ***P b 0.001 compared with control group.(Fig. 1);morphine injection at 3 and 6mg/kg 30min before the formalin
test significantly reduced formalin-induced nociceptive behaviors in
phase 1 (p b 0.05), interphase (for morphine at 3mg/kg, p b 0.01; and
for morphine at 6mg/kg, p b 0.001), and phases 2A and 2B (p b 0.001)
compared with the control group (Fig. 1). Moreover, the injection of
10mg/kg morphine completely suppressed formalin-induced nocicep-
tive behaviors in both phases 1 and 2 (pb0.001).3.2. Effects of different doses of SB-334867 (ICV) on morphine-induced an-
algesia in formalin test
Fig. 2 demonstrates the results of experiment 2. Morphine injection
at 1.5mg/kg before the formalin test, significantly decreased formalin-
induced nociceptive behaviors in phase 1 (p b 0.05), interphase
(p b 0.001), and phase 2A (p b 0.05) compared with the control group
(Fig. 2). Pre-treatment with orexin receptor type-1 antagonist, SB-
334867 at a dose of 0.5 nmol significantly attenuated morphine-
induced analgesia in interphase (pb0.05, Fig. 2), and phase 2B compared
with the control group (pb0.05, Fig. 2). Pre-treatmentwith SB-334867 at
a dose of 5nmol, significantly attenuatedmorphine-induced analgesia in
interphase (p b 0.05) and when used at a higher dose (50 nmol),
morphine-induced analgesia was considerably attenuated in phase 1
(pb 0.05), interphase (pb 0.01), and the first and second parts of phase
2 compared with the control group (pb0.01, Fig. 2).
Fig. 3 shows the results of experiment 3. The injection of 3mg/kg of
morphine alone produced antinociceptive behaviors in the formalin test
as demonstrated by a substantial decrease in the nociceptive behavior
in phase 1 (p b 0.05), interphase (p b 0.01), and the first and second
parts of phase 2 compared with the control group (p b 0.001, Fig. 3).
Also, pre-treatment with SB-334867 at a dose of 0.5 nmol remarkably
attenuated morphine-induced analgesia in phase 2B when compared
with the control group (p b 0.05). In addition, the administration of
SB-334867 at a dose of 5 nmol significantly attenuated morphine-
induced analgesia in phase 1 (p b 0.05), interphase (p b 0.05), and the
first (p b 0.05) and the second parts of phase2 (pb 0.01). Furthermore,
pre-treatment with SB-334867 at a dose of 50nmol notably attenuated
morphine-induced analgesia in phase 1 (p b 0.001), interphase
(p b 0.05), and the first and second parts of phase 2 when compared
to the control group (pb0.01, Fig. 3).
Finally, Fig. 4 illustrates the results of experiment 4 in which the
injection of 6 mg/kg of morphine alone produced antinociceptive be-
haviors in the formalin test as revealed by a considerable decrease in no-
ciceptive behavior in phase1 (pb0.001), interphase (pb0.001), and the
first and second parts of phase 2 compared with the control groupcutaneous injection ofmorphine (1.5. 3, 6, and 10mg/kg)measured every 3min for 90min
hase 1 (minutes 1–7), inter-phase (minutes 8–14), phase 2A (minutes 15–60), and phase 2
ceptive behaviors began immediately after formalin injection (time 0) and continued for
Fig. 2. Formalin-induced nociceptive behaviors (mean± SEM of 6–8 rats per group) following ICV administration of SB-334867 (0.5, 5 and 50 nmol)+morphine 1.5 mg/kg, measured
every 3min for 90min (A), the bar chart for each phase (B). In B section, the columns represent the average nociceptive scores in each phase: phase 1 (minutes 1–7), inter-phase (minutes
8–14), phase 2A (minutes 15–60) and phase 2 (minutes 61–90). Rats received morphine 30min before formalin injection. Recording of nociceptive behaviors began immediately after
formalin injection (time 0) and continued for 90min. *Pb 0.05; **P b 0.01 and ***P b 0.001 compared with control group. †P b 0.05; ††P b 0.01 and †††P b 0.001 compared with morphine
induced analgesia group.
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0.5 nmol produced no significant attenuation of morphine-induced
antinociceptive effect in the formalin test (p N 0.05, Fig. 4). Also, pre-
treatment with SB-334867 at a dose of 5nmol considerably attenuated
morphine-induced analgesia at the first (p b 0.05) and second parts of
phase 2 (pb0.01). Furthermore, SB-334867 at a dose of 50nmol signif-
icantly attenuated morphine-induced analgesia in phase 1 (p b 0.001)
and phase 2B when compared to the control group (pb0.001, Fig. 4).
To investigate the effect of different doses of orexin receptor type-1
on the antinociceptive effect of different doses of morphine, we ana-
lyzed our data for phase 1 (min 0–7) and phase 2 (min 15–90) and
the results were included in Table 1 in which the reversal percentages
of morphine-induced antinociception by different doses of SB-334867
are shown. As demonstrated in Table 1, the ICV administration of
SB-334867 at 0.5 nmol failed to produce any effect on antinociceptive
responses of morphine (1.5, 3 and 6 mg/kg) in phase 1 [F (2, 16) =
0.552, P=0.590], and phase 2 [F (2, 16)=3.852, P=0.079], revealed
by one-way ANOVA and the Newman–Keuls multiple comparison
tests. The ICV administration of SB-334867 at 5 nmol failed to produce
any effect on the antinociceptive responses of morphine (1.5, 3 and
6 mg/kg) in phase 1 [F (2, 17) = 1.466, P = 0.281] but showed aFig. 3. Formalin-induced nociceptive behaviors (mean±SEMof 6–8 rats per group) following IC
3min for 90min (A), the bar chart for eachphase (B). In B section, the columns represent the ave
phase 2A (minutes 15–60) and phase 2 (minutes 61–90). Rats receivedmorphine 30min befor
injection (time 0) and continued for 90min. *P b 0.05; **P b 0.01 and ***P b 0.001 compared wi
analgesia group.significant effect on phase 2 [F (2, 17)=6.873, P=0.052], demonstrated
by one-way ANOVA and the Newman–Keuls multiple comparison tests.
One-way ANOVA followed by the Newman–Keuls multiple comparison
tests showed that the antinociceptive response of morphine (1.5, 3 and
6 mg/kg) was suppressed by the injection of SB-334867 at 50 nmol
concentration in phase 1 [F (2, 15) = 15.489, P = 0.000] and phase 2
[F (2, 15)=12.313, Pb0.001] (Table 1.).
The injection of 10mg/kgmorphine completely suppressed formalin-
induced nociceptive behaviors in both phases 1 and 2 (pb0.001, Fig. 1).
Pre-treatment with SB-334867 at doses of 0.5, 5, and 50nmol produced
no significant attenuation of morphine-induced antinociceptive effect at
10mg/kg in the formalin test (pN0.05, data not shown).
4. Discussion
It is well-known that morphine induced analgesia is mediated
through (direct and indirect) spinal and supraspinal sites (Yaksh and
Noueihed, 1985; Dafny et al., 1996; Franco and Prado, 1996). Investiga-
tions reported from several laboratories support the involvement of
orexin-A in the modulation of nociceptive behavior (Yamamoto et al.,
2003b; Holland et al., 2005; Mobarakeh et al., 2005a,b; Chiou et al.,V administration of SB-334867 (0.5, 5 and 50nmol)+morphine 3mg/kg,measured every
rage nociceptive scores in eachphase: phase 1 (minutes 1–7), inter-phase (minutes 8–14),
e formalin injection. Recording of nociceptive behaviors began immediately after formalin
th control group. †P b 0.05; ††P b 0.01 and †††P b 0.001 compared with morphine induced
Fig. 4. Formalin-induced nociceptive behaviors (mean±SEMof 6–8 rats per group) following ICV administration of SB-334867 (0.5, 5 and 50nmol)+morphine 6mg/kg,measured every
3min for 90min (A), the bar chart for eachphase (B). In B section, the columns represent the average nociceptive scores in eachphase: phase 1 (minutes 1–7), inter-phase (minutes 8–14),
phase 2A (minutes 15–60) and phase 2 (minutes 61–90). Rats receivedmorphine 30min before formalin injection. Recording of nociceptive behaviors began immediately after formalin
injection (time 0) and continued for 90min. *P b 0.05; **P b 0.01 and ***P b 0.001 compared with control group. †P b 0.05; ††P b 0.01 and †††P b 0.001 compared with morphine induced
analgesia group.
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2013). The present investigation was designed to determine the possi-
ble involvement of orexin in morphine induced antinociception. In the
current study, the subcutaneous administration of morphine (1.5, 3, 6,
10 mg/kg S.C.) produced clear dose-related antinociceptive effects as
evaluated by the formalin test. The antinociceptive effects of morphine
administrationwere decreased by a selective orexin receptor type-1 an-
tagonist, SB-334867 (0.5, 5 and 50nmol; ICV) but not in a dose depen-
dent manner. These results suggest that some parts of the analgesic
effect of morphine are mediated by orexinergic system through the ac-
tivation of orexin receptor type-1. The involvement of the orexinergic
systemwhichmediates themorphine antinociception, as demonstrated
in the present investigation, iswell supported by previous studies. It has
been reported that orexin-A reduces the level of thermal hyperalgesia in
the mouse carrageenan test and produces an analgesic effect in the
mouse hot plate test. These effects of orexin-A which are mediated by
the activation of orexin receptor type-1, as SB-334867 and not nalox-
one, prevent orexin-A induced analgesia (Bingham et al., 2001). Yama-
moto et al. in 2002 and 2003 showed that the application of orexin-A
produced an anti-mechanical allodynic effect and decreased both the
thermal hyperalgesia induced by the paw carrageen injection and the
formalin-induced nociceptive behaviors. Naloxone pre-treatment pro-
duced no effect on the antinociceptive effect of orexin-A in the formalin
test in rats (Yamamoto et al., 2002, 2003a). In another study, they also
showed that orexin-A has an anti-mechanical allodynia induced by
the partial sciatic nerve ligation (a model of neuropathic pain) in rats
(Yamamoto et al., 2003a). There are several documents that demon-
strate that both the spinal and supraspinal mechanisms contribute
to the antinociceptive effects of orexin-A (Bingham et al., 2001;
Yamamoto et al., 2002, 2003a; Azhdari-Zarmehri et al., 2011; Erami
et al., 2012a). This is consistent with the localization of orexin receptor
type-1 in the nociceptive area of the spinal cord and the brain (Peyron
et al., 1998; Trivedi et al., 1998; Hervieu et al., 2001). A previousTable 1
Reversal percentages of morphine induced antinociception by different doses of SB-334867 in t
SB-334867 SB-334867 0.5 nmol SB-334867
Morphine Phase 1 Phase 2 Phase 1
Mor 1.5 0.3± 11.1 37.1± 16.1 −12.6± 10
Mor 3 −0.6± 22.5 943.7± 296.2* 24.3± 8.1
Mor 6 −7.5± 16.1 −10.8± 43.4 7.1± 8.2study in our lab showed that stress-induced antinociceptive effect is
prevented by SB-334867 (Heidari-Oranjaghi et al., 2012) and the antag-
onism of orexin receptor type-1decreased the development of mor-
phine tolerance and dependence (Erami et al., 2012b).
In the present study, our results showed that pre-treatment with
SB-334867 (0.5, 5 and 50 nmol) reversed the analgesic effect of mor-
phine in a dose dependent manner, however, several previous studies
have shown that naloxone pre-treatment had no effect on the analgesic
effect of orexin-A induced analgesia (Bingham et al., 2001; Yamamoto
et al., 2002; Cheng et al., 2003). This led us to suggest that the analgesic
effect of orexin-A was unlikely to be mediated by endogenous opioid
system at the supra-spinal and spinal cord levels and instead, the
antinociceptive effect of morphine in the formalin test may have been
caused by the modulation of orexin-A pathway in the brain or/and spi-
nal cord. This is consistent with the facts that: 1) Electrical or chemical
stimulations of LH were found to produce an analgesic effect (Fuchs
and Melzack, 1995; Dafny et al., 1996; Holden and Pizzi, 2008). 2) the
microinjection of morphine into LH also produced an analgesic effect
(Fuchs and Melzack, 1995; Dafny et al., 1996; Holden and Pizzi, 2008).
3) orexin-A has an important role in pain modulation and is reported
to produce an analgesic effect (Chiou et al., 2010; Azhdari-Zarmehri
et al., 2011; Erami et al., 2012a). 4) Previous studieswith in-situ hybrid-
ization have indicated that the μ-opioid receptor is expressed in the LH
region; Georgescu et al. (2003) used immunofluorescence with double-
labeling to examine the presence of μ-opioid receptors on orexin cells in
the LH (Georgescu et al., 2003).
The excitatory effect of morphine on orexin neurons of LH might not
be due to the direct effect of morphine on excitatory synapse transmis-
sion, but may result from the inhibition on interneurons, as disinhibition
mechanism that has been described in other regions of brain (Fields et al.,
1983; Zhu et al., 2008). For example; activation of mu opioid receptor
effect on inhibitory recurrent circuits in the dentate gyrus and therewith,
indirectly plays a regulatory role for excitatory neurotransmissionhe formalin test. ⁎ Pb0.05 and ⁎⁎ Pb0.01 for the significance of asterisk in the below table.
5 nmol SB-334867 50nmol
Phase 2 Phase 1 Phase 2
.3 14.9± 24.5 12.0± 7.8 73.9± 19.8
* 869.0± 203.1* 50.8± 12.4* 1577.6± 217.6*
* 81.1± 46.2 90.2± 20.2** 13.9± 44.5
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aptic disinhibition is one possible mechanism by which morphine in-
creases neurotransmitter release in the brain nuclei (Zhu et al., 2008).
Orexin-induced analgesia involves both spinal and supraspinal
mechanisms. The dens projections of orexin cells to the marginal
zone, lamina 1, and the entire segments of the spinal cord proposed
that orexinmay be implicated in pain processing and thermal sensation
(van den Pol, 1999). In some sections of Van Den Pol's study, some cells
of the marginal zone were restricted by the orexin-immunoreactive
boutons, suggesting that orexin fibers selectively innervate subpopula-
tions of cells in themarginal zonewhichmight either be associatedwith
a spatial sensation, pain information, or modulating specific ascending
fibers (Cedarbaum and Aghajanian, 1978; Narotzky and Kerr,
1978). Supraspinal analgesia involves effects of orexin-A at the
level of the PAG. The intra-PAG administration of orexin A produced
an antinociceptive effect which was blocked by SB 334867 (Azhdari-
Zarmehri et al., 2011; Ho et al., 2011) or AM 251 (Ho et al., 2011). In
the slices of the ventrolateral PAG, orexin-A, through the receptor 1, sup-
pressed the GABAergic induced inhibitory postsynaptic current. The
postsynaptic OX1 receptor activation in the ventrolateral PAG can en-
gage a Gq-protein coupled PLCβ-DAGLα enzymatic pathway to produce
2-AG, leading to a disinhibition phenomenon followed by activating the
top-down descending pain inhibitory pathway, and these in turn
explain the analgesic effect of orexin-A in the ventrolateral PAG (Ho
et al., 2011).
Our result also showed that the ICV injection of SB-334867 alonehad
no effect on the formalin test at the doses usually used to antagonize the
analgesic effect of orexin-A in the formalin test. In this respect, our
results are consistent with a previous study that showed that the intra-
thecal injection of SB-334867 alone had no effect in both formalin and
hot plate tests (Yamamoto et al., 2002). However, our findings are
incompatible with those of Bingham et al. (2001) in which it was dem-
onstrated that the intraperitoneal injection of SB-334867 produced a
pro-hyperalgesic effect in the mouse carrageenan-induced thermal
hyperalgesia test (Binghamet al., 2001). Based on a report by Yamamoto
et al. in 2002, these data might suggest that a tonic orexin-A inhibitory
system does not exist in the central nervous system during the formalin
test (Yamamoto et al., 2002) however, theremay be a tonically activated
orexin-A inhibitory system present during a carrageenan-induced ther-
mal hyperalgesia test in mice (Bingham et al., 2001). To justify this
difference, there are several possibilities: Although both subcutaneous
formalin injection and carrageenan injection induce a localized inflam-
mation, nevertheless the formalin injection of the paw induces a noci-
ceptive behavior for about 1 h (Wheeler-Aceto et al., 1990; Yamamoto
and Yaksh, 1992) whereas the edema induced by the paw carrageenan
injection lasts longer than the formalin test and in addition, the ther-
mal hyperalgesia in the carrageenan test occurs about 2 h after the
injection (Wheeler-Aceto et al., 1990; Yamamoto and Yaksh, 1992;
Yamamoto et al., 2002). This may reflect the strain differences, dif-
ferent routes of administration, differences between the models
used (carrageenan hyperalgesia and formalin tests), and methodologi-
cal differences (e.g. lighting, noise, odors, handling stress or anesthesia
prior to formalin injection and might differences in data collection
times between laboratories; all known to influence the test).
In conclusion, based on the findings of both the previous and the
present studies, we would like to suggest that the orexinergic system
might provide a possible pathway for morphine induced analgesia,
promising a new potential therapeutic target in the treatment of pain.
However, further in vitro and in vivo studies are necessary to clarify
how the orexinergic system is involved in morphine pain modulation.
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